SCHEMBL17366642

SCHEMBL17366642

Cc1[nH]c2ccccc2c1-c1nc2c3cc([N+](=O)[O-])ccc3c3ccc([N+](=O)[O-])cc3c2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GABRP O00591 1/20 0.46
GABRD O14764 1/20 0.46
GABRA1 P14867 1/20 0.46
GABRB1 P18505 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA5 P31644 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
GABRA4 P48169 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14023716 0.98 MEN1 (0.46) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL14023445 0.98 MAPT (0.46) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL10067288 0.85 GABRA1 (0.47) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL17366639 0.81 MEN1 (0.51) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL14023554 0.81 PTGES (0.56) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL14023651 0.81 MEN1 (0.51) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL10067338 0.80 MEN1 (0.61) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL17366638 0.79 ELANE (0.54) MAPTGABRPGABRDGABRA1GABRB1
SCHEMBL14023485 0.78 PTGES (0.58) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL14220769 0.78 MEN1 (0.51) MEN1KMT2AMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS LORUS THERAPEUTICS INC. (CA) 2015-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150374669-A1 ARYL IMIDAZOLES AND THEIR USE AS ANTI-CANCER AGENTS AHR, CBR3, AADAC MEN1 4554/4885KMT2A 362/4885MAPT 4768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.